Search

Author/Creator Cataldi, F

2. DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II. (25th January 2019)

Authors:
Reinisch, W; Sandborn, W J; Danese, S; Hébuterne, X; Kłopocka, M; Tarabar, D; Vaňásek, T; Greguš, M; Hellstern, P A; Kim, J S; Sparrow, M; Gorelick, K J; Goetsch, M; Bliss, C; Gupta, C; Cataldi, F; Vermeire, S
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S056
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn's disease: data from the CELEST study. (25th January 2019)

Authors:
Peyrin-Biroulet, L; Danese, S; Louis, E; Higgins, P D R; Dubinsky, M; Cataldi, F; Zhou, Q; Lee, W-J; Kligys, K; Lacerda, A P
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S057
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis. (25th January 2019)

Authors:
Reinisch, W; Sandborn, W J; Danese, S; Hébuterne, X; Kłopocka, M; Tarabar, D; Vaňásek, T; Greguš, M; Hellstern, P A; Kim, J S; Sparrow, M; Gorelick, K J; Goetsch, M; Bliss, C; Gupta, C; Cataldi, F; Vermeire, S
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S058
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. OP022 Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST study. (16th January 2018)

Authors:
Schreiber, S; Peyrin-Biroulet, L; Boland, B; Higgins, P D; Armuzzi, A; Terdiman, J; Zhou, W; Alperovich, G; Cataldi, F; Goteti, S; Lacerda, A P
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S015
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn's disease: the OPERA II study. (16th January 2018)

Authors:
D'Haens, G R; Reinisch, W; Lee, S D; Tarabar, D; Louis, E; Kłopocka, M; Klaus, J; Schreiber, S; Park, D I; Hébuterne, X; Cataldi, F; Banerjee, A; Gorelick, K; Sandborn, W J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S017
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. OP08 Long-term efficacy and pharmacodynamics of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn's disease: the OPERA II study. (25th January 2019)

Authors:
D'Haens, G; Reinisch, W; Lee, S D; Tarabar, D; Louis, E; Kłopocka, M; Klaus, J; Schreiber, S; Park, D I; Hébuterne, X; Gorelick, K J; Martin, S W; Banerjee, A; Nagy, P; Wang, Y; Cataldi, F; Sandborn, W J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S005
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study. (25th January 2019)

Authors:
Sandborn, W J; Schreiber, S; Lee, S D; Lindsay, J O; Hebuterne, X; Zhou, W; Cataldi, F; Lacerda, A P; Huang, B; Xie, W; Loftus Jr, E V
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S009
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P283 Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinib. (25th January 2019)

Authors:
Ghosh, S; Louis, E; Loftus Jr, E V; Reinisch, W; Cataldi, F; Zhou, W; Lee, W-J; Panes, J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S240
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P435 Rapidity of symptomatic and inflammatory biomarker improvements following upadacitinib induction treatment: data from the U-ACHIEVE study. (25th January 2019)

Authors:
D'Haens, G; Loftus Jr, E V; Higgins, P D R; Panes, J; Panaccione, R; Zhou, W; Cataldi, F; Lee, W-J; Huang, B; Xie, W; Vermeire, S
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S326
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗